Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer’s disease

Table 1 Demographic information for enrolled clinically suspected early stage AD subjects

Amyloid PET	Positive	Negative	All
Numbers (% female)	22 (50.0%)	30 (36.7%)	52 (42.3%)
Age (years)	72.1 ± 7.6	71.9 ± 9.7	72.0 ± 8.8
Education (years)	12.0 ± 4.3	11.0 ± 3.6	11.4 ± 3.9
Clinical stage
aMCI	8	25	33
Mild dementia	14	5	19
APOE ε4 carrier	12	2	14
CDR	0.5	0.5	0.5
MMSE	24.0 ± 2.7	27.0 ± 2.2^†	25.8 ± 2.8
Logical memory delayed recall	5.41 ± 3.92	8.40 ± 5.12*	7.13 ± 4.84

Abbreviations: AD Alzheimer’s disease, CDR Clinical Dementia Rating Scale, MMSE Mini-Mental State Examination, PET positron emission tomography
*P value < 0.05
^†P value < 0.001

ISSN: 1758-9193